## NSW Cancer Research Education

**Statewide Seminar Series 2024** Tuesday 20 August 12.30 - 1.30 pm

## Appendiceal neoplasms: Shedding light on a rare disease



**A/Prof Kate Mahon**Director of Medical Oncology
Chris O'Brien Lifehouse



**Dr Madeleine Strach**Medical Oncologist
Chris O'Brien Lifehouse



Dr Dannel Yeo
Senior Research Officer, Centenary Institute
Lecturer, University of Sydney
Research Scientist, Roayl Prince Alfred Hospital

Chair: Dr Cassandra White

Medical Oncology Staff Specialist, Maitland Hospital





**REGISTER NOW** 

Supported by the Cancer Institute NSW Translation Cancer Research Capacity Building Grants









## **Session Information**

Appendiceal neoplasms are rare, poorly researched and have a wide range of outcomes. This seminar will discuss the varied subtypes of disease, current treatment options and our research program that aims to better understand the biology, develop useful tumour models and ultimately define new therapeutics.

## **Speakers**



**A/Prof Kate Mahon** is Director of Medical Oncology at the Chris O'Brien Lifehouse and a post-doctoral researcher at the University of Sydney and the Garvan Institute. She specialises in appendiceal, colorectal and prostate cancers and leads the peritoneal malignancy translational research program that includes RPA Hospital, Chris O'Brien Lifehouse, Centenary and Garvan Institutes.

**Dr Madeleine Strach** is a medical oncologist at Chris O'Brien Lifehouse with a special interest in appendiceal cancer and bone and soft tissue tumours. She recently submitted her PhD on appendiceal malignancies through the University of Sydney which involved clinical and translational research in both Sydney (RPA/Chris O'Brien Lifehouse/Garvan Institute) and Manchester, UK (Christie NHS Foundation Trust).





**Dr Dannel Yeo** is a translational researcher specifically focusing on improving patient management and outcomes in rare cancers. He is a senior research officer at the Centenary Institute, lecturer at University of Sydney and research scientist at Royal Prince Alfred Hospital. His research program examines liquid biopsy biomarkers and generates patient-derived tumour models to identify the most effective treatments for cancer patients.



Cancer

Clinical Academic Group



